Previous reports have been published of increased cutaneous absorption of tacrolimus in children with concomitant conditions associated with a skin-barrier dysfunction. Our case is the first report on toxic levels of tacrolimus after topical administration in a child with severe cutaneous acute GVHD. An 11-month-old boy who underwent unrelated umbilical cord blood stem cell transplantation for a SCID received topical tacrolimus for severe cutaneous GVHD. After only two applications restricted to the upper extremities, tacrolimus serum levels reached 23.4 ng/ml. Serum levels rapidly decreased following discontinuation of the topical tacrolimus. No adverse effects related to tacrolimus toxic levels were observed. This case report suggests that significant topical tacrolimus absorption may occur in some children with concomitant conditions displaying skin-barrier dysfunction. Drug monitoring of tacrolimus should be considered in children with extensive skin lesions treated with topical tacrolimus to adjust appropriately dosage.
A child was diagnosed at 5 months of age with SCID. At 7 months, he underwent unrelated umbilical cord blood hematopoietic stem cell transplantation (HSCT) for the treatment of this condition. He presented 30 days later with gastrointestinal and cutaneous involvement resulting in a global grade 3 acute GVHD. More than 10 stools per day were reported (600 ml/m 2 /day) corresponding to grade 2 gastrointestinal GVHD. The cutaneous condition covered more than 50% of his body surface (cutaneous GVHD grade 3). The lesions were very erythematous with superficial desquamation but were not denuded and there were no apparent vesicles or ulcerations. As part of the HSCT protocol, he had received cyclosporine with steroids as GVHD prophylaxis. The GVHD was treated initially with cyclosporine and high-dose corticosteroids. Cyclosporine was switched 2 months after his HSCT to tacrolimus owing to intolerance to intravenous cyclosporine and variable therapeutic levels with the oral formulation. Several drugs were used in combination to treat his GVHD such as mycophenolate mofetil, infliximab, daclizumab and thymoglobulin. The response to these treatments was very limited, with some treatments showing only short-term efficacy.
Oral tacrolimus was started at a standard dose of 0.15 mg/kg/day, but high tacrolimus levels were observed, probably due to diarrhea as reported previously. 1 After lowering the dose of tacrolimus to 0.05 mg/kg/day, therapeutic levels were achieved (5-10 ng/ml) and were stable. Since severe acute cutaneous GVHD covered 100% of his body surface and limited response of other GVHD treatments was observed, topical tacrolimus 0.1% twice daily was added. The patient was 11 months old at that time. After only two applications on the upper extremities, tacrolimus levels jumped from 6.4 to 23.4 ng/ml. Oral tacrolimus was stopped immediately. The next day, topical tacrolimus was discontinued, because serum levels had reached 28.8 ng/ml. Topical tacrolimus was not stopped right away because of the presumed minimal topical absorption. Three days after discontinuation, the tacrolimus level had decreased to 5.8 ng/ml and oral tacrolimus was resumed, achieving stable therapeutic levels. Ten days later, topical tacrolimus was prescribed again. Less than 36 h after application limited to the legs, tacrolimus levels jumped from 6.4 to 18.3 ng/ml. Topical and oral tacrolimus were both stopped, and 2 days later, the tacrolimus level was 6.6 ng/ml. Topical tacrolimus resulted in a localized clinical effect limited to the administration area. No adverse effects related to tacrolimus toxic levels were observed. Toxic levels were observed without any concomitant aggravation of the gastrointestinal GVHD, which could have increased oral absorption. 1 Protopic (manufacturer Astellas Pharma Canada Inc., Markham, ON, Canada) is officially indicated for children older than 2 years of age. The most frequently adverse events reported in children are skin burning and pruritus. 2 Cutaneous absorption was minimal in the clinical trials (98% of pediatric patients had blood concentrations below 2 ng/ml). 3 Increased cutaneous absorption can be attributed to the severely damaged skin. Previous reports of increased cutaneous absorption have been published in children (28 months to 15 years) with concomitant conditions associated with a skin barrier dysfunction: Netherton syndrome (three cases, tacrolimus levels between 10.2 and 37.2 ng/ml), lamellar ichtyosis (one case, 19.3 ng/ml, 3 h after application) and orofacial Crohn disease (9 ng/ml after oral mucosis administration). [4] [5] [6] [7] Even after extemporaneously compounding 0.005 and 0.01%, significant cutaneous absorption was observed in three children with Netherton syndrome. 8 Our case is the first case report on toxic levels of tacrolimus after topical administration in a child who underwent an unrelated umbilical cord blood HSCT and presented a severe cutaneous GVHD. The levels of tacrolimus of this patient were stable before the introduction of the topical form and then became toxic. Those levels were probably due to the topical administration since they continued to increase even 24 h after oral tacrolimus was stopped. This phenomenon reappeared when the topical administration was restarted. This example shows that therapeutic drug monitoring should be considered in children with topical tacrolimus and extensive skin lesions. 
